{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80"}]}],"title":"Overall Number Baseline Subjects"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"Serious Adverse Events"},{"categories":[{"measurements":[{"groupId":"OG000","value":"57"}]}],"title":"Non-Serious Adverse Events"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Death (all causes)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Death Resulting from Adverse Events"}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"}],"units":"Participants"}],"description":"AEs are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome, or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards.","groups":[{"description":"NEOD001, 24 mg/kg IV every 4 weeks","id":"OG000","title":"NEOD001 24 mg/kg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"OLE Safety Population","reportingStatus":"POSTED","timeFrame":"Each subject's study participation may have been up to 36 months or until the study was terminated","title":"Number of Participants With Adverse Events","type":"PRIMARY","unitOfMeasure":"Participants"}